Plain-English translation of NCT06006390 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CAR-T cell therapy, a treatment that uses your own immune cells modified to recognize and destroy cancer cells that have a specific marker called CEA. Researchers will collect some of your blood cells, reprogram them in a laboratory to target your cancer, and then give them back to you through an infusion. The goal is to see if this personalized treatment can shrink tumors and help people with advanced cancers that haven't responded to standard treatments.
Many patients with advanced solid tumors stop responding to chemotherapy and other standard treatments, leaving them with limited options. This medication represents a new approach that harnesses the body's own immune system to attack cancer cells in a way that's highly personalized to each patient.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn so doctors can collect and reprogram your immune cells in a laboratory (a process that takes several weeks). Once your cells are ready, you will receive an infusion of these modified cells either through an IV in your arm or directly into your abdominal cavity, depending on which group you are assigned to. You will then be monitored closely with blood tests, imaging scans, and clinic visits to check how well the treatment is working and watch for any side effects. The trial is divided into two phases: first, a small group will receive the treatment to confirm it is safe, and then a larger group will receive it to further test its effectiveness.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China